Individual Heterogeneity Screened Umbilical Cord Derived Mesenchymal Stem Cells With High Treg Promotion Significantly Recovered the Mouse Liver Fibrosis

Yuanyuan Xie,Shuo Liu,Liudi Wang,Hui Yang,Chenxu Tai,Li Ling,Libo Chen,Shanshan Liu,Bin Wang
DOI: https://doi.org/10.21203/rs.3.rs-225190/v1
2021-01-01
Abstract:Abstract BackgroundTo compare the heterogeneities of human umbilical cord mesenchymal stem cells (HUCMSCs) derived from different donors and test their therapeutic variations in mouse liver fibrosis model. MethodsThe HUCMSCs derived multiple donors were performed comprehensively analysis and potent assays including expressions of surface markers, viability, growth curve, karyotype analysis, tumorigenicity, differentiation potentials, and immune regulation capability. Then the HUCMSCs with distinct immunomodulatory effects were tested for treating liver fibrosis in mice and then therapeutic effects were observed. ResultsThe HUCMSCs derived multiple donors kept a high consistency in surface marker expressions, viability, growth curve, tumorigenicity in nude mic, but had robust heterogeneities in differentiation potentials and immune regulations. In addition, three HUCMSC lines applied to mice liver fibrosis model had different therapeutic outcomes, in line with individual immune regulation capability. ConclusionThe HUCMSCs derived different donors have individual heterogeneity, which potentially lead to distinct therapeutic outcomes in mouse liver fibrosis, indicating we could make use of the donor-variation of MSCs to screen out guaranteed general indicators of MSCs for specific diseases in further stem cell therapy.
What problem does this paper attempt to address?